Jump to content

Draft:Jeffrey V. Lazarus

From Wikipedia, the free encyclopedia
  • Comment: Using Al Jazeera and Financial Times home page as sources is not appropriate. This reads more like a WP:CV than an encyclopedic article. Needs personal information. Where is he from? When was he born? Ktkvtsh (talk) 00:05, 27 August 2024 (UTC)

Jeffrey V. Lazarus is a professor of Health Policy and Management[1]at the CUNY Graduate School of Public Health & Health Policy (CUNY SPH).[2] He is also research professor and head of the Public Health Liver Group[3] at the Barcelona Institute for Global Health (ISGlobal). His research and advocacy focuses on international health systems, viral hepatitis, HIV, and COVID-19.

Education

[edit]

Lazarus earned his doctor of medicine (PhD) degree in public health at Lund University (Sweden). He received a master of international health (MIH) degree from the University of Copenhagen (Denmark),[4] and a master of arts (MA) in political science from Georgetown University.

Career

[edit]

Prior to joining CUNY SPH, Lazarus worked as a Senior Researcher and later a Professor at CHIP–The Center for Health and Infectious Disease Research[5] in Denmark, where he helped launch the WHO Collaborating Center on HIV and Viral Hepatitis[6] at the University of Copenhagen. Prior, he acted as Honorary Professor at the London School of Hygiene and Tropical Medicine and was Chief Researcher at the Lithuanian University of Health Services,[7] European Commission FP7 CERCA research project, Latin America (2013-14). He helped lead various projects, including the European Joint Action on HIV, TB, and hepatitis (HA-REACT),[8] and the Hep-NORDIC Study.[9] Between 2015 and 2018, he was Board Chair of the AIDS Foundation East-West (AFEW).[10] From 2012 to 2014, he was an Independent Review Committee Member of the GAVI Alliance.[11]

From March 2012 to 2015, he co-founded and directed the secretariat of Health Systems Global, an international professional society focused on health systems.

In 2009, he joined the Global Fund to Fight AIDS, Tuberculosis, and Malaria in Geneva, Switzerland to serve first as Team Leader (for Publications and Learning Team) before transitioning to Senior Policy Officer (Grade 6).

Lazarus joined the WHO Regional Office for Europe in Denmark[12] in 1998, where he remained through 2009. From 2008 to 2009, as Senior Advocacy and Community Relations Officer in the Communicable Diseases Unit, Lazarus managed all aspects of knowledge translation, organized major WHO events, and represented the WHO at advisory forums, steering committees, and meetings. From 2005 to 2008, as an Advocacy and Community Relations Officer in the STI/HIV/AIDS program, he coordinated all publications and conference participation for the programme's 35+ staff, including the first major WHO consultations with the HIV community, on the criminalization of HIV (Copenhagen, 2006) and on MSM and HIV (Slovenia, 2008). He also organized WHO Europe's input into World AIDS Day and World Hepatitis Day – co-hosting the first one in 2006.

Research and Advocacy

[edit]

HIV/AIDS

[edit]

Lazarus' career as a health systems, HIV and viral hepatitis expert at WHO's Regional Office for Europe was followed by three years at the Global Fund to Fight AIDS, Tuberculosis, and Malaria. He also served as founding co-chair of the HIV Outcomes Beyond Viral Suppression coalition from 2016 to 2024. He has authored numerous publications in this area, including the global consensus statement on HIV and health systems.[13] He also led The Lancet HIV series on HIV Beyond Viral Suppression,[14] and was on the editorial board of HIV Medicine and the International Journal of Drug Policy.

COVID-19

[edit]

In 2022 Lazarus led a Nature-published study on ending COVID-19 as a public health threat.[15] It comprised a diverse, multidisciplinary panel of 386 academic, health, non-governmental organizations, government and other experts in COVID-19 response from 112 countries and territories to recommend specific actions to stop this global threat to public health. He published multiple studies on COVID-19 vaccine hesitancy including in Nature Medicine[16][17] and Nature Communications.[18]

Liver Health

[edit]

Lazarus has led advancements in prevention, testing, care, and treatment of viral hepatitis across Europe, Africa and the United States. He co-founded the European Viral Hepatitis Elimination Coalition (ACHIEVE)[19] and contributed to the first WHO viral hepatitis strategy.[20] He launched the HCV micro-elimination approach[21] while serving as vice-chair of the EASL. International Liver Foundation and participated in both Lancet Gastroenterology and Hepatitis Commissions on viral hepatitis.[22]

He has played a central role in liver health for steatotic liver disease including metabolic dysfunction–associated steatotic liver disease [MASLD] and metabolic dysfunction-associated steatohepatitis (MASH). He co-authored the non-alcoholic fatty liver disease (NAFLD) public health consensus statement[23] published in Nature Reviews Gastroenterology & Hepatology in 2021, and led the development of new nomenclature for fatty liver disease published in three major society journals in June 2023.[24][25] Lazarus also helped lead in establishing global research priorities in the Journal of Hepatology[26] and action priorities in Hepatology,[27] both in 2023.

Awards and Honors

[edit]

In 2017, Lazarus received the Economist Intelligence Unit Change Maker Award[28] for contributions to the global elimination of hepatitis C.

In 2019, he was awarded the Spanish Ministry of Science, Innovation and Universities Miguel Servet grant to continue advancing his research at ISGlobal.

In 2023, he received the American Liver Foundation's Distinguished Scientific Achievement Award.[29]

Publications and Media

[edit]

Jeffrey V Lazarus has published over 400 peer-reviewed articles and book chapters.[30] During the COVID-19 pandemic he was cited >500 times in newspapers (including El País, the Financial Times,[31] le Monde,[31] the New York Times and the Wall St Journal) and appeared on major TV networks including Al Jazeera,[32] the BBC, Euronews, Sky News, and Spanish TV1,2 and Antenna 3.[33]

References

[edit]
  1. ^ "Jeffrey Lazarus". CUNY Graduate School of Public Health & Health Policy. Retrieved 2024-08-26.
  2. ^ "Homepage". CUNY Graduate School of Public Health & Health Policy.
  3. ^ "Health systems, viral hepatitis, HIV and COVID-19". ISGLOBAL.
  4. ^ Copenhagen, University of (June 29, 2016). "University of Copenhagen". www.ku.dk.
  5. ^ "CHIP – Centre of Excellence for Health, Immunity and Infections". chip.dk.
  6. ^ https://www.rki.de/EN/Content/Institute/WHOCC/WHO_CC_Virushepatitis_HIV.html#:~:text=As%20a%20WHO%20collaborating%20center,in%20the%20WHO%20European%20region.
  7. ^ "Home". LSMU.
  8. ^ "HA-REACT | AAE". www.aidsactioneurope.org.
  9. ^ Safreed-Harmon, Kelly; Hetherington, Kristina L.; Aleman, Soo; Alho, Hannu; Dalgard, Olav; Frisch, Tove; Gottfredsson, Magnus; Weis, Nina; Lazarus, Jeffrey V.; Hep-Nordic Study Group (2018). "Policy responses to hepatitis C in the Nordic countries: Gaps and discrepant reporting in the Hep-Nordic study". PLOS ONE. 13 (1): e0190146. Bibcode:2018PLoSO..1390146S. doi:10.1371/journal.pone.0190146. ISSN 1932-6203. PMC 5790214. PMID 29381697.
  10. ^ "AFEW International". AFEW. August 15, 2024.
  11. ^ "Gavi, the Vaccine Alliance". www.gavi.org. August 15, 2024.
  12. ^ "About us". www.who.int.
  13. ^ Lazarus, Jeffrey V.; Safreed-Harmon, Kelly; Kamarulzaman, Adeeba; Anderson, Jane; Leite, Ricardo Baptista; Behrens, Georg; Bekker, Linda-Gail; Bhagani, Sanjay; Brown, Darren; Brown, Graham; Buchbinder, Susan; Caceres, Carlos; Cahn, Pedro E.; Carrieri, Patrizia; Caswell, Georgina (2021-07-16). "Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIV". Nature Communications. 12 (1): 4450. Bibcode:2021NatCo..12.4450L. doi:10.1038/s41467-021-24673-w. ISSN 2041-1723. PMID 34272399.
  14. ^ Safreed-Harmon, Kelly; Anderson, Jane; Azzopardi-Muscat, Natasha; Behrens, Georg M N; d'Arminio Monforte, Antonella; Davidovich, Udi; del Amo, Julia; Kall, Meaghan; Noori, Teymur; Porter, Kholoud; Lazarus, Jeffrey V (1 December 2019). "Reorienting health systems to care for people with HIV beyond viral suppression". The Lancet HIV. 6 (12): e869–e877. doi:10.1016/s2352-3018(19)30334-0. ISSN 2352-3018. PMID 31776099.
  15. ^ Lazarus, Jeffrey V.; Romero, Diana; Kopka, Christopher J.; Karim, Salim Abdool; Abu-Raddad, Laith J.; Almeida, Gisele; Baptista-Leite, Ricardo; Barocas, Joshua A.; Barreto, Mauricio L.; Bar-Yam, Yaneer; Bassat, Quique; Batista, Carolina; Bazilian, Morgan; Chiou, Shu-Ti; del Rio, Carlos (1 November 2022). "A multinational Delphi consensus to end the COVID-19 public health threat". Nature. 611 (7935): 332–345. Bibcode:2022Natur.611..332L. doi:10.1038/s41586-022-05398-2. ISSN 1476-4687. PMC 9646517. PMID 36329272.
  16. ^ Lazarus, Jeffrey V.; Ratzan, Scott C.; Palayew, Adam; Gostin, Lawrence O.; Larson, Heidi J.; Rabin, Kenneth; Kimball, Spencer; El-Mohandes, Ayman (20 October 2020). "A global survey of potential acceptance of a COVID-19 vaccine". Nature Medicine. 27 (2): 225–228. doi:10.1038/s41591-020-1124-9. ISSN 1546-170X. PMC 7573523. PMID 33082575.
  17. ^ Lazarus, Jeffrey V.; Wyka, Katarzyna; White, Trenton M.; Picchio, Camila A.; Gostin, Lawrence O.; Larson, Heidi J.; Rabin, Kenneth; Ratzan, Scott C.; Kamarulzaman, Adeeba; El-Mohandes, Ayman (9 January 2023). "A survey of COVID-19 vaccine acceptance across 23 countries in 2022". Nature Medicine. 29 (2): 366–375. doi:10.1038/s41591-022-02185-4. ISSN 1546-170X. PMID 36624316.
  18. ^ Lazarus, Jeffrey V.; Wyka, Katarzyna; White, Trenton M.; Picchio, Camila A.; Rabin, Kenneth; Ratzan, Scott C.; Parsons Leigh, Jeanna; Hu, Jia; El-Mohandes, Ayman (2022-07-01). "Revisiting COVID-19 vaccine hesitancy around the world using data from 23 countries in 2021". Nature Communications. 13 (1): 3801. Bibcode:2022NatCo..13.3801L. doi:10.1038/s41467-022-31441-x. ISSN 2041-1723. PMID 35778396.
  19. ^ "Achieve – Associations Collaborating on Hepatitis to Immunize and Eliminate the Viruses in Europe".
  20. ^ "Global health sector strategy on viral hepatitis 2016-2021. Towards ending viral hepatitis". www.who.int. Retrieved 2024-08-26.
  21. ^ Lazarus, Jeffrey V.; Safreed-Harmon, Kelly; Thursz, Mark R.; Dillon, John F.; El-Sayed, Manal H.; Elsharkawy, Ahmed M.; Hatzakis, Angelos; Jadoul, Michel; Prestileo, Tullio; Razavi, Homie; Rockstroh, Jürgen K.; Wiktor, Stefan Z.; Colombo, Massimo (9 July 2018). "The Micro-Elimination Approach to Eliminating Hepatitis C: Strategic and Operational Considerations". Seminars in Liver Disease. 38 (3): 181–192. doi:10.1055/s-0038-1666841. ISSN 0272-8087. PMID 29986353.
  22. ^ Cooke, Graham S; Andrieux-Meyer, Isabelle; Applegate, Tanya L; Atun, Rifat; Burry, Jessica R; Cheinquer, Hugo; Dusheiko, Geoff; Feld, Jordan J; Gore, Charles; Griswold, Max G; Hamid, Saeed; Hellard, Margaret E; Hou, JinLin; Howell, Jess; Jia, Jidong (2 February 2019). "Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission". The Lancet Gastroenterology & Hepatology. 4 (2): 135–184. doi:10.1016/s2468-1253(18)30270-x. ISSN 2468-1253. PMID 30647010.
  23. ^ Lazarus, Jeffrey V.; Mark, Henry E.; Anstee, Quentin M.; Arab, Juan Pablo; Batterham, Rachel L.; Castera, Laurent; Cortez-Pinto, Helena; Crespo, Javier; Cusi, Kenneth; Dirac, M. Ashworth; Francque, Sven; George, Jacob; Hagström, Hannes; Huang, Terry T.-K.; Ismail, Mona H. (10 January 2021). "Advancing the global public health agenda for NAFLD: a consensus statement". Nature Reviews Gastroenterology & Hepatology. 19 (1): 60–78. doi:10.1038/s41575-021-00523-4. ISSN 1759-5053. PMID 34707258.
  24. ^ Schattenberg, Jörn M.; Allen, Alina M.; Jarvis, Helen; Zelber-Sagi, Shira; Cusi, Ken; Dillon, John F.; Caussy, Cyrielle; Francque, Sven M.; Younossi, Zobair; Alkhouri, Naim; Lazarus, Jeffrey V. (2023-01-03). "A multistakeholder approach to innovations in NAFLD care". Communications Medicine. 3 (1): 1–5. doi:10.1038/s43856-022-00228-y. ISSN 2730-664X. PMID 36596859.
  25. ^ Rinella, Mary E.; Lazarus, Jeffrey V.; Ratziu, Vlad; Francque, Sven M.; Sanyal, Arun J.; Kanwal, Fasiha; Romero, Diana; Abdelmalek, Manal F.; Anstee, Quentin M.; Arab, Juan Pablo; Arrese, Marco; Bataller, Ramon; Beuers, Ulrich; Boursier, Jerome; Bugianesi, Elisabetta (1 December 2023). "A multisociety Delphi consensus statement on new fatty liver disease nomenclature". Hepatology. 78 (6): 1966–1986. doi:10.1097/HEP.0000000000000520. ISSN 0270-9139. PMC 10653297. PMID 37363821.
  26. ^ Lazarus, Jeffrey V.; Mark, Henry E.; Allen, Alina M.; Arab, Juan Pablo; Carrieri, Patrizia; Noureddin, Mazen; Alazawi, William; Alkhouri, Naim; Alqahtani, Saleh A.; Arrese, Marco; Bataller, Ramon; Berg, Thomas; Brennan, Paul N.; Burra, Patrizia; Castro-Narro, Graciela E. (19 June 2023). "A global research priority agenda to advance public health responses to fatty liver disease". Journal of Hepatology. 79 (3): 618–634. doi:10.1016/j.jhep.2023.04.035. ISSN 0168-8278. PMID 37353401.
  27. ^ Lazarus, Jeffrey V.; Mark, Henry E.; Allen, Alina M.; Arab, Juan Pablo; Carrieri, Patrizia; Noureddin, Mazen; Alazawi, William; Alkhouri, Naim; Alqahtani, Saleh A.; Anstee, Quentin M.; Arrese, Marco; Bataller, Ramon; Berg, Thomas; Brennan, Paul N.; Burra, Patrizia (2 February 2024). "A global action agenda for turning the tide on fatty liver disease". Hepatology. 79 (2): 502–523. doi:10.1097/HEP.0000000000000545. ISSN 0270-9139. PMC 10789386. PMID 37540183.
  28. ^ "Jeffrey Lazarus Honoured as HCV Change Maker by the Economist Intelligence Unit". ISGLOBAL. Retrieved 2024-08-26.
  29. ^ "American Liver Foundation Honors Professor Jeffrey V Lazarus, PhD with the Distinguished Scientific Achievement Award - American Liver Foundation". liverfoundation.org. 2023-11-07. Retrieved 2024-08-26.
  30. ^ "Jeffrey V Lazarus".
  31. ^ a b "Financial Times". www.ft.com.
  32. ^ "Breaking News, World News and Video from Al Jazeera". Al Jazeera.
  33. ^ "Antena 3 - La Televisión Líder en España | Noticias, Programas y Series". Antena3.
Retrieved from "https://wiki.riteme.site/w/index.php?title=Draft:Jeffrey_V._Lazarus&oldid=1242680390"